These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 35482079)

  • 1. MemAID: Memory advancement with intranasal insulin vs. placebo in type 2 diabetes and control participants: a randomized clinical trial.
    Novak V; Mantzoros CS; Novak P; McGlinchey R; Dai W; Lioutas V; Buss S; Fortier CB; Khan F; Aponte Becerra L; Ngo LH
    J Neurol; 2022 Sep; 269(9):4817-4835. PubMed ID: 35482079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Memory advancement by intranasal insulin in type 2 diabetes (MemAID) randomized controlled clinical trial: Design, methods and rationale.
    Galindo-Mendez B; Trevino JA; McGlinchey R; Fortier C; Lioutas V; Novak P; Mantzoros CS; Ngo L; Novak V
    Contemp Clin Trials; 2020 Feb; 89():105934. PubMed ID: 31923471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of Intranasal Insulin in Type 2 Diabetes on Systemic Insulin: A Double-Blinded Placebo-Controlled Sub-Study of Memaid Trial.
    Aponte Becerra L; Galindo Mendez B; Khan F; Lioutas V; Novak P; Mantzoros CS; Ngo LH; Novak V
    Arch Diabetes Obes; 2022; 4(2):403-415. PubMed ID: 35903156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of vasoreactivity and cognition by intranasal insulin in type 2 diabetes.
    Novak V; Milberg W; Hao Y; Munshi M; Novak P; Galica A; Manor B; Roberson P; Craft S; Abduljalil A
    Diabetes Care; 2014; 37(3):751-9. PubMed ID: 24101698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and preliminary efficacy of intranasal insulin for cognitive impairment in Parkinson disease and multiple system atrophy: A double-blinded placebo-controlled pilot study.
    Novak P; Pimentel Maldonado DA; Novak V
    PLoS One; 2019; 14(4):e0214364. PubMed ID: 31022213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daily intranasal insulin at 40IU does not affect food intake and body composition: A placebo-controlled trial in older adults over a 24-week period with 24-weeks of follow-up.
    Becerra LA; Gavrieli A; Khan F; Novak P; Lioutas V; Ngo LH; Novak V; Mantzoros CS
    Clin Nutr; 2023 Jun; 42(6):825-834. PubMed ID: 37084469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A feasibility study of the combination of intranasal insulin with oral semaglutide for cognition in older adults with metabolic syndrome at high dementia risk- Study rationale and design.
    Davidy T; Yore I; Cukierman-Yaffe T; Ravona-Springer R; Livny A; Lesman-Segev OH; Azuri Y; Carmichael O; Kapogiannis D; Zetterberg H; Lin H; Sano M; Beeri MS
    Mech Ageing Dev; 2024 Apr; 218():111898. PubMed ID: 38159613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A feasibility study of the combination of intranasal insulin with dulaglutide for cognition in older adults with metabolic syndrome at high dementia risk - Study rationale and design.
    Davidy T; Yore I; Cukierman-Yaffe T; Ravona-Springer R; Livny A; Lesman-Segev OH; Azuri Y; Carmichael O; Kapogiannis D; Zetterberg H; Lin H; Sano M; Beeri MS
    Mech Ageing Dev; 2023 Jul; 213():111825. PubMed ID: 37245533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once-Weekly Insulin Icodec vs Once-Daily Insulin Degludec in Adults With Insulin-Naive Type 2 Diabetes: The ONWARDS 3 Randomized Clinical Trial.
    Lingvay I; Asong M; Desouza C; Gourdy P; Kar S; Vianna A; Vilsbøll T; Vinther S; Mu Y
    JAMA; 2023 Jul; 330(3):228-237. PubMed ID: 37354562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
    Dahl D; Onishi Y; Norwood P; Huh R; Bray R; Patel H; Rodríguez Á
    JAMA; 2022 Feb; 327(6):534-545. PubMed ID: 35133415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
    Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of a herbal drug of Coccinia grandis (Linn.) Voigt in patients with type 2 diabetes mellitus: A double blind randomized placebo controlled clinical trial.
    Wasana KGP; Attanayake AP; Weerarathna TP; Jayatilaka KAPW
    Phytomedicine; 2021 Jan; 81():153431. PubMed ID: 33352495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.
    Buse JB; Klonoff DC; Nielsen LL; Guan X; Bowlus CL; Holcombe JH; Maggs DG; Wintle ME
    Clin Ther; 2007 Jan; 29(1):139-53. PubMed ID: 17379054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dropout risk and effectiveness of retention strategies in the Memory Advancement by Intranasal Insulin in Type 2 Diabetes (MemAID) Clinical Trial.
    Isaza-Pierrotti DF; Khan F; Novak P; Lioutas V; Mantzoros CS; Ngo LH; Novak V
    Contemp Clin Trials; 2023 Feb; 125():107057. PubMed ID: 36539060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, Efficacy, and Feasibility of Intranasal Insulin for the Treatment of Mild Cognitive Impairment and Alzheimer Disease Dementia: A Randomized Clinical Trial.
    Craft S; Raman R; Chow TW; Rafii MS; Sun CK; Rissman RA; Donohue MC; Brewer JB; Jenkins C; Harless K; Gessert D; Aisen PS
    JAMA Neurol; 2020 Sep; 77(9):1099-1109. PubMed ID: 32568367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.
    Wilding JP; Woo V; Rohwedder K; Sugg J; Parikh S;
    Diabetes Obes Metab; 2014 Feb; 16(2):124-36. PubMed ID: 23911013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes.
    Buse JB; Rubin CJ; Frederich R; Viraswami-Appanna K; Lin KC; Montoro R; Shockey G; Davidson JA
    Clin Ther; 2005 Aug; 27(8):1181-95. PubMed ID: 16199244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.
    Derosa G; Cicero AF; Gaddi AV; Ciccarelli L; Piccinni MN; Salvadeo S; Pricolo F; Fogari E; Ghelfi M; Ferrari I; Fogari R
    Clin Ther; 2005 Sep; 27(9):1383-91. PubMed ID: 16291411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy.
    Barnett AH; Charbonnel B; Li J; Donovan M; Fleming D; Iqbal N
    Clin Drug Investig; 2013 Oct; 33(10):707-17. PubMed ID: 23949898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CCR2 antagonism in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.
    Di Prospero NA; Artis E; Andrade-Gordon P; Johnson DL; Vaccaro N; Xi L; Rothenberg P
    Diabetes Obes Metab; 2014 Nov; 16(11):1055-64. PubMed ID: 24798870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.